Dear editor

We read with great interest the article entitled "May IL-17 have a role in COVID-19 infection?" published by M. Megna et al. [@b0005].

Increased levels of plasma pro-inflammatory cytokines such as interleukin IL 6 are observed in Covid 19 subjects; this condition represents the rationale for the use of tocilizumab, a monoclonal antibody blocking IL-6 [@b0005], [@b0010]. Special attention for other cytokines that could reduce COVID-19 impact, in particular IL 17, is growing [@b0005], because IL 6 and IL17 synergistically prevent apoptosis of infected cells and promote the virus persistence [@b0015].

Balestri et al. reported a clinical case of a patient that during therapy with an IL-17 inhibitor resulted positive for SARS-CoV-2, despite being completely asymptomatic, and that continued biological therapy suggesting that the inhibition of IL-17 pathway may have beneficial effects in treating COVID-19 and that it does not negatively affect the primary phase of infection [@b0020].

We report a case of a 57 year old man with psoriatic arthritis treated with Methotrexate and Secukinumab who in April 2020 reports fever, dyspnea, ageusia, anosmia and conjunctivitis; he was tested for SARS-CoV-2 and he resulted positive. For the rapid worsening of clinical symptoms, the patient was hospitalized, intubated and treated with mechanical ventilation and antiviral therapy. There was a gradual and progressive improvement with extubation and subsequent discharge. Biohumoral tests documented lymphocytopenia and increase of reactants of the acute phase with IL 6 levels always normal. In our case report, unlike what reported by Balestri, IL 17 inhibitor was not protective against the progression of the infection, resulting in ARDS (Acute distress respiratory Syndrome). In this patient low IL 6 values were found, at all stages of the disease, suggesting that other cytokines and mechanisms may have a role in critical COVID- 19 patients which progress to multiple organ dysfunction.
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